These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 9778086)
41. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
43. IIb/IIIa receptor blockade in acute myocardial infarction. Ferguson JJ; Taqi K Am Heart J; 1999 Aug; 138(2 Pt 2):S164-70. PubMed ID: 10426877 [TBL] [Abstract][Full Text] [Related]
44. Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina. Steinhubl SR; Moliterno DJ Heart Vessels; 1997; Suppl 12():148-55. PubMed ID: 9476567 [TBL] [Abstract][Full Text] [Related]
45. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Harrington RA Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244 [TBL] [Abstract][Full Text] [Related]
46. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836 [TBL] [Abstract][Full Text] [Related]
47. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Akkerhuis KM; Neuhaus KL; Wilcox RG; Vahanian A; Boland JL; Hoffmann J; Baardman T; Nehmiz G; Roth U; Klootwijk AP; Deckers JW; Simoons ML; Eur Heart J; 2000 Dec; 21(24):2042-55. PubMed ID: 11102255 [TBL] [Abstract][Full Text] [Related]
48. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
49. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Zhao XQ; Théroux P; Snapinn SM; Sax FL Circulation; 1999 Oct; 100(15):1609-15. PubMed ID: 10517731 [TBL] [Abstract][Full Text] [Related]
50. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
51. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients. Tricoci P; Peterson ED J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570 [TBL] [Abstract][Full Text] [Related]
52. Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes. Kugelmass AD Curr Opin Hematol; 1997 Sep; 4(5):301-5. PubMed ID: 9288461 [TBL] [Abstract][Full Text] [Related]
53. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Tricoci P; Newby LK; Kandzari DE; Harrington RA Expert Rev Cardiovasc Ther; 2007 May; 5(3):401-12. PubMed ID: 17489665 [TBL] [Abstract][Full Text] [Related]
58. [Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results]. Peter K; Nordt T; Bode C Z Kardiol; 2000; 89 Suppl 7():60-9. PubMed ID: 11098561 [TBL] [Abstract][Full Text] [Related]
59. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466 [TBL] [Abstract][Full Text] [Related]
60. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ; Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]